Ferrocene-based drug dimer nano therapeutic agent as well as preparation method and application thereof

Through multimodal strategies to regulate iron ions, amino acids and glutathione metabolism in tumor cells, multimodal iron death nanoinducers were prepared, which solved the problem of insufficient iron death effect in colorectal cancer treatment, significantly enhanced the treatment effect and inhibited tumor growth .

CN118930591AActive Publication Date: 2024-11-12ZHUJIANG HOSPITAL OF SOUTHERN MEDICAL UNIVERSITY
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202411180097.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-27
Publication Date
2024-11-12
Estimated Expiration
2044-08-27

AI Technical Summary

Technical Problem

Prior Art In the treatment of colorectal cancer, the therapeutic effect of iron death is affected by the intrinsic resistance of tumor cells to iron. There is a shortage of the integration of single or dual methods to enhance the pathway of iron death, making it difficult to maximize the therapeutic effect.

Method used

Multimodal strategy is adopted to prepare multimodal ferrodynamic nanoinducers by regulating iron ions, amino acids and glutathione anabolic in tumor cells, using self-assembled Fc-ss-SN38 and Fc-ss-SAS and DSPE-PEG2k Combined, spherical nanoparticles are formed to enhance the therapeutic effect of iron death.

Benefits of technology

It significantly improves the ferrodysensitivity of colorectal cancer cells, enhances the therapeutic effect by regulating multiple metabolic pathways, and releases drugs through GSH response, significantly inhibits tumor growth.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118930591A_ABST
    Figure CN118930591A_ABST
Patent Text Reader

Abstract

The invention provides a ferrocene-based drug dimer nano therapeutic agent as well as a preparation method and application thereof, belongs to the technical field of drug development, provides a drug delivery system based on a ferrocene drug dimer, and particularly develops a multi-mode ferroptosis nano inducer (FSS). And the potential of inducing ferroptosis to treat colorectal cancer is explored. The ferrocene modified SAS prodrug and the SN38 prodrug are prepared by chemically coupling SAS or SN38 and ferrocenedicarboxylic acid through esterification reaction of bis (2-hydroxyethyl) disulfide, the prodrug has the characteristic of responding to high-level GSH specific release in a tumor microenvironment, and pharmacokinetic and pharmacokinetic characteristics of clinically approved drugs are optimized. The clinical drug dimer based on ferrocene has a certain self-assembly characteristic, the two drug dimers are co-assembled to prepare a nano therapeutic agent with combined application potential, and the nano therapeutic agent has good application potential and prospect in colorectal cancer treatment.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical fields of material science, synthesis of functional nanomaterials, regulation of assembly morphology, treatment of colorectal cancer, drug delivery, and the like, and specifically to a multimodal ferroptosis nanoinducer and a preparation method and application thereof, and in particular to a method for preparing a spherical multimodal ferroptosis nanoinducer by assembling the Fc-ss-SN38 and Fc-ss-SAS. Background Art

[0002] Colorectal cancer has rapidly evolved into a major global health problem, and its etiology is closely related to the progress of industrialization. Emerging research has positioned ferroptosis as a powerful antitumor modality, introducing a critical pathway for colorectal cancer management. However, glutathione peroxidase 4 (GPX4) and solute carrier family 7 member 11 (SLC7A11) are significantly upregulated in colorectal cancer tissues compared with normal colon tissues, indicating that intrinsic resistance to ferroptosis weakens the therapeutic effect. To resolve this therapeutic impasse, it is necessary to enhance the sensitivity of colorectal cancer cells to ferroptosis. Four major sensitization strategies have been described: (1) modulation of iron metabolism, (2) regulation of ferroptosis-related lipid metabolism, (3) manipulation of amino acid metabolism, and (4) strict control of glutathione synthesis and degradation. The first two sensitization strategies discussed above enhance the lipid peroxide generation system, while the latter two strategies impair the lipid peroxide clearance system. In this context, the key to iron metabolism is to enhance the chelation of endogenous iron and the meticulous targeting of exogenous iron to tumor sites, thereby amplifying the efficacy of ferroptosis through local cellular iron overload. In addition, the regulation of ferroptosis-related lipid metabolism is mainly achieved through lipid peroxidation catalyzed by enzymes such as arachidonic acid 12-lipoxygenase (ALOX12). At the same time, the regulation of amino acid metabolism is mainly achieved by inhibiting glutaminase activity and limiting the uptake of specific amino acids, especially cystine, thereby reducing the concentration of intracellular reduced glutathione (GSH) and weakening tumor resistance to ferroptosis. During lipid peroxidation, highly reactive lipid free radicals are produced, which enhance ferroptosis. Despite these advances, cancer cells show a remarkable ability to activate compensatory mechanisms after amino acid inhibition, aiming to restore GSH synthesis through alternative biochemical pathways. Therefore, the increased sensitivity to ferroptosis has shifted to regulating GSH metabolism. This requires not only the consumption of excess reduced glutathione, but also the inhibition of glutathione regeneration from oxidized glutathione (GSSG), which together reduce glutathione reserves in tumor cells and amplify the ferroptosis response.

[0003] These pathways intersect and mutually influence ferroptosis in tumor cells. However, integrating these pathways to enhance ferroptosis through single or dual approaches is insufficient in maximizing therapeutic efficacy. We therefore propose an integrated multimodal strategy to enhance ferroptosis by simultaneously modulating the metabolism of iron ions, amino acids, and glutathione synthesis in tumor cells to significantly improve therapeutic indices. A pragmatic approach to bring this strategy closer to clinical application is to use existing clinical drugs as the primary reference for drug selection and combination therapy, namely drug repurposing, which utilizes mature drugs with known safety profiles for new oncology uses. Drug repurposing has emerged as an important and promising strategy in cancer therapy, providing important insights into strategic drug selection and synergistic combinations. However, implementing drug repurposing in cancer therapy to achieve clinically potential multimodal ferroptosis-enhancing strategies remains a considerable challenge. Summary of the invention

[0004] In view of the shortcomings of current single or dual approaches to integrate ferroptosis pathways to enhance ferroptosis in maximizing therapeutic effects, we proposed a comprehensive multimodal strategy to enhance ferroptosis by simultaneously regulating the metabolism of iron ions, amino acids, and glutathione synthesis in tumor cells, and prepared a multimodal ferroptosis nanoinducer to significantly improve therapeutic indicators. A pragmatic approach to bring this strategy closer to clinical application is to use existing clinical drugs as the main reference for drug selection and combination therapy, that is, drug repurposing, that is, using mature drugs with known safety for new oncology uses.

[0005] The specific scheme adopted by the present invention is:

[0006] In the first aspect, the present invention provides a ferrocene-based drug dimer nanotherapeutic agent, which is formed into nanoparticles by self-assembly of Fc-ss-SN38 and Fc-ss-SAS, and by introducing DSPE-PEG 2k Prepared; The Fc-ss-SN38 and Fc-ss-SAS are obtained by chemically coupling SN38 or SAS with ferrocene dicarboxylic acid via bis(2-hydroxyethyl) disulfide, and the structural formula is as follows:

[0007] In a second aspect, the present invention provides a method for preparing the above-mentioned ferrocene-based drug dimer nanotherapeutic agent, comprising the following steps: (1) Dissolve Fc-ss-SN38 and Fc-ss-SAS in tetrahydrofuran to obtain two prodrug solutions; 2k Dissolve in tetrahydrofuran to obtain DSPE-PEG 2k Solution; (2) The prodrug solution obtained in step (1) and DSPE-PEG 2k The solutions were mixed, slowly dripped into pure water, and stirred at room temperature overnight to obtain the multi-modal ferroptosis nanoinducer.

[0008] As a further optimization of the above preparation method, in step (1), the concentration of the prodrug solution is 1-5 mg / mL, more preferably 5 mg / mL; the DSPE-PEG 2k The concentration of the solution is 1-5 mg / mL, more preferably 5 mg / mL.

[0009] As a further optimization of the above preparation method, in step (2), the volume ratio of the Fc-ss-SN38 prodrug solution to the Fc-ss-SAS prodrug solution is 1:9, 1:4, 1:1, 4:1 or 9:1, more preferably 4:1.

[0010] As a further optimization of the above preparation method, in step (2), the reaction temperature is 4-60°C, more preferably 25°C; the reaction time is 12-48h, more preferably 24h.

[0011] As a further optimization of the above preparation method, the Fc-ss-SN38 or Fc-ss-SAS can be replaced by Fc-ss-AA, Fc-ART, Fc-ss-PTX, Fc-ss-IMI, Fc-ss-R848, Fc-ss-TRA, Fc-ss-CEL, Fc-ss-ATRA, etc. These ferrocene-based drug dimers also have self-assembly and co-assembly properties, and a series of multifunctional nanotherapeutics can be prepared.

[0012] In a third aspect, the present invention provides the use of the above-mentioned ferrocene-based drug dimer nanotherapeutic agent in any of the following: (1) Multimodal induction of ferroptosis in colorectal cancer cells; (2) Preparation of drugs for the treatment of colorectal cancer.

[0013] Compared with the prior art, the present invention has the following beneficial effects:

[0014] 1. An innovative multimodal ferroptosis nanoinducer (FSS) was developed using the clinically relevant drugs SN38 and sulfasalazine.

[0015] 2. FSS exerts its effects by regulating multiple pathways, including iron metabolism, amino acid metabolism, and glutathione synthesis.

[0016] 3.FSS has the ability to release drugs in response to GSH and is effective in treating colorectal cancer. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] Figure 1 This is the TEM image of FSS provided in Example 1.

[0018] Figure 2 This is a statistical graph showing the cytotoxicity of FSS to CT26 cells provided in Application Example 1.

[0019] Figure 3 This is a statistical graph of Annexin V-FITC / PI double staining of CT26 cells by FSS provided in Application Example 1 and subsequent flow cytometry analysis.

[0020] Figure 4 This is the result of the cell scratch experiment of FSS on CT26 cells provided in Application Example 1.

[0021] Figure 5 This is the analysis result diagram of the effect of FSS on the MDA content of CT26 cells provided in Application Example 1.

[0022] Figure 6 This is the analysis result diagram of the effect of FSS on Fe(II) content in CT26 cells provided in Application Example 1.

[0023] Figure 7 This is the analysis result diagram of the effect of FSS on the cysteine ​​content of CT26 cells provided in Application Example 1.

[0024] Figure 8 This is the analysis result of the effect of FSS on the GSH content of CT26 cells provided in Application Example 1.

[0025] Fig. 9 This is the result diagram of the in vivo anti-tumor effect of FSS on CT26 subcutaneous tumor-bearing mice provided in Application Example 2.

[0026] Fig.10 This is the analysis result of the effect of FSS on Ki-67 expression in vivo in CT26 subcutaneous tumor-bearing mice provided in Application Example 2.

[0027] Fig.11 This is the analysis result of the effect of FSS on the in vivo tumor Tunel expression of CT26 subcutaneous tumor-bearing mice provided in Application Example 2.

[0028] Fig.12 This is a graph showing the results of the analysis of the effect of FSS provided in Application Example 2 on the in vivo tumor GPX4 protein expression in CT26 subcutaneous tumor-bearing mice.

[0029] Fig.13 This is the analysis result diagram of the effect of FSS on the in vivo tumor Nrf2 protein expression in CT26 subcutaneous tumor-bearing mice provided in Application Example 2.

[0030] Fig.14This is the result diagram of the in vivo anti-tumor effect of FSS on CT26 colon orthotopic tumor-bearing mice provided in Application Example 2.

[0031] Fig.15 This is the analysis result of the effect of FSS on Ki-67 expression in vivo in CT26 colon orthotopic tumor-bearing mice provided in Application Example 2.

[0032] Fig.16 This is the analysis result of the effect of FSS on the in vivo tumor Tunel expression in CT26 colon orthotopic tumor-bearing mice provided in Application Example 2.

[0033] Fig.17 This is a graph showing the results of the analysis of the effect of FSS provided in Application Example 2 on the in vivo tumor GPX4 protein expression in CT26 colon orthotopic tumor-bearing mice.

[0034] Fig.18 This is the analysis result of the effect of FSS provided in Application Example 2 on the in vivo tumor Nrf2 protein expression in CT26 colon orthotopic tumor-bearing mice. DETAILED DESCRIPTION

[0035] In this study, we identified SN38, an active metabolite of irinotecan, a widely used chemotherapeutic drug, and sulfasalazine (SAS), a therapeutic drug for ulcerative colitis, as our candidate drugs for multimodal ferroptosis-enhanced CRC treatment. By conjugating ferrous iron to SN38 and SAS, respectively, through disulfide bonds, we synthesized for the first time two prodrugs that can self-assemble into GSH-responsive nanodrugs, thereby creating an innovative multimodal ferroptosis nanoinducer (i.e., ferrocene-based drug dimer nanotherapeutic). First, the camptothecin derivative SN38 not only inhibits topoisomerase I, hinders tumor cell proliferation and induces cell apoptosis, but also regulates key proteins in ferroptosis: it downregulates nuclear transcription factor erythroid 2-related factor 2 (Nrf2), reduces GSH production and inhibits GPX4 activity, thereby attenuating lipid peroxide decomposition and promoting ferroptosis. At the same time, SN38 upregulates p53 and enhances the expression of arachidonic acid ALOX12, thereby promoting the accumulation of lipid peroxides and promoting the ferroptosis process. SAS is an FDA-approved ferroptosis inducer that acts by inhibiting SLC7A11 and reducing cysteine ​​influx (a GSH precursor), thereby promoting ferroptosis. Therefore, upon entering tumor cells, nanocomposite FSS modulates the lipid peroxide generation and clearance system due to disrupting amino acid and iron metabolism and reduces GSH levels, thereby significantly increasing the accumulation of intracellular lipid peroxides. This multimodal effect significantly enhances ferroptosis in colorectal cancer cells. In summary, the multimodal ferroptosis inducer FSS depicts a novel and promising approach for the development of colorectal cancer treatment by utilizing induced ferroptosis to enhance the efficacy of chemotherapy.

[0036] The present invention provides a multi-mode ferroptosis nano-inducer, wherein the raw materials for preparing the multi-mode ferroptosis nano-inducer include: Fc-ss-SN38, Fc-ss-SAS, DSPE-PEG 2k and solvents.

[0037] In the present invention, Fc-ss-SN38 and Fc-ss-SAS are self-assembled to form spherical particles, and DSPE-PEG is introduced into the spherical particles. 2k The stability of the nanoparticles was enhanced to become a multi-modal ferroptosis nano-inducer, which made the assembled spherical particles show good anti-colorectal cancer performance. The effectiveness of the prepared multi-modal ferroptosis nano-inducer was further determined, which has a certain guiding role in the subsequent preparation of multi-modal ferroptosis nano-inducers.

[0038] The structural formulas of Fc-ss-SN38 and Fc-ss-SAS are as follows:

[0039] Wherein, the preparation process of Fc-ss-SN38 (or Fc-ss-SAS) is as follows: (1) adding bis(2-hydroxyethyl) disulfide and tert-butyldimethylsilyl chloride (TBSCl) to a DMF solution containing imidazole, and after the reaction is completed, column chromatography is performed for purification to obtain a colorless liquid compound 1; (2) Dissolve ferrocenedicarboxylic acid in DCM, add EDC and stir for 10 min, then add DMAP and compound 1. After the reaction is completed, column chromatography is performed to obtain compound 2 as a light yellow oil; (3) Add triethylamine trihydrofluoric acid to the THF solution of compound 2, stir at room temperature, and after the reaction is completed, column chromatography is performed to obtain a yellow oily compound 3; (4) adding p-nitrophenyl chloroformate to a DCM solution of compound 3 containing DIPEA, and after completion of the reaction at room temperature, column chromatography was performed to obtain compound 4; (5) SN38 (or SAS) is added to a DCM solution of compound 4 containing DIPEA. After the reaction is completed at room temperature, compound 5 is obtained by column chromatography, namely Fc-ss-SN38 (or Fc-ss-SAS).

[0040] Preferably, the multi-mode ferroptosis nanoinducer is formed into spherical particles by self-assembly of Fc-ss-SN38 and Fc-ss-SAS, and DSPE-PEG is introduced into the spherical particles. 2k The stability of the nanoparticles is enhanced.

[0041] Preferably, the multimodal ferroptosis nanoinducer is a nanosphere.

[0042] Preferably, the particle size of the nanospheres is about 150 nm.

[0043] Preferably, the Fc-ss-SN38, Fc-ss-SAS and DSPE-PEG 2k The purity is 98% or more, for example, 98%, 98.5%, 99%, 99.5%, etc.

[0044] Preferably, the solvent is water, preferably deionized water.

[0045] The present invention assembles Fc-ss-SN38 and Fc-ss-SAS into nanoparticles, and introduces DSPE-PEG 2k Enhance the stability of nanoparticles and prepare multi-mode ferroptosis nanoinducers. This method uses ferrocene dicarboxylic acid (FCCa) modified SN38 / SAS and DSPE-PEG 2k As raw materials, a multi-mode ferroptosis nano-inducer is prepared in deionized water. The preparation method of the present invention is simple and easy to operate, and the preparation is completed in an environmentally friendly aqueous solution. No other components need to be introduced during the preparation process. The prepared multi-mode ferroptosis nano-inducer has uniform size and is evenly dispersed.

[0046] Preferably, in step (1), the concentration of the Fc-ss-SN38 or Fc-ss-SAS prodrug solution is 1-5 mg / ml, for example, 1 mg / ml, 2 mg / ml, 3 mg / ml, 4 mg / ml, 5 mg / ml, etc., preferably 5 mg / ml.

[0047] Preferably, in step (1), the DSPE-PEG 2k The concentration of the solution is 1-5 mg / ml, for example, 1 mg / ml, 2 mg / ml, 3 mg / ml, 4 mg / ml, 5 mg / ml, etc., preferably 5 mg / ml.

[0048] Preferably, in step (2), the volume ratio of the Fc-ss-SN38 prodrug solution to the Fc-ss-SAS prodrug solution is 1:9; 1:4; 1:1; 4:1; 9:1, preferably 4:1.

[0049] Preferably, in step (2), the reaction temperature is 4-60°C (for example, it can be 4°C, 5°C, 6°C, 8°C, 10°C, 12°C, 14°C, 16°C, 18°C, 20°C, 22°C, 24°C, 26°C, 28°C, 30°C, 35°C, 40°C, 45°C, 50°C, 55°C, 60°C, etc.), preferably 25°C, and the reaction time is 12-48h (for example, it can be 12h, 14h, 16h, 18h, 20h, 22h, 24h, 26h, 28h, 30h, 35h, 40h, 45h, 48h, etc.), preferably 24h.

[0050] Preferably, the method for preparing the multi-mode ferroptosis nanoinducer comprises the following steps:

[0051] (1) dissolving the Fc-ss-SN38 prodrug solution and the Fc-ss-SAS prodrug solution with a purity of more than 98% in tetrahydrofuran to obtain a 1-5 mg / ml prodrug solution; 2k Dissolve in tetrahydrofuran to obtain 1-5 mg / ml DSPE-PEG 2k Solution;

[0052] (2) The prodrug solution obtained in step (1) and DSPE-PEG 2k The solutions are mixed in a volume ratio of 1:9; 1:4; 1:1; 4:1; 9:1, and reacted at 4-60° C. for 12-48 hours to obtain the multi-mode ferroptosis nanoinducer.

[0053] The structural formulas of other ferrocene-based drug dimers Fc-ss-AA, Fc-ART, Fc-ss-PTX, Fc-ss-IMI, Fc-ss-R848, Fc-ss-TRA, Fc-ss-CEL, and Fc-ss-ATRA are shown below:

[0054] These ferrocene-based drug dimers also have self-assembly and co-assembly properties, and new nanotherapeutics based on such drug dimers can be developed to improve the shortcomings of the original drugs in clinical applications.

[0055] The present invention further provides a use of the multi-modal ferroptosis nanoinducer in the treatment of colorectal cancer.

[0056] In the present invention, the specific steps of the multi-mode ferroptosis nanoinducer in the treatment of colorectal cancer are:

[0057] (A) The multimodal ferroptosis nanoinducers were added to the culture system of colorectal cancer cells and incubated for 24 hours. Cytotoxicity assay, scratch assay, flow cytometry apoptosis assay, and ferroptosis-related indicators (malondialdehyde, glutathione, and iron ion content) were then tested.

[0058] (B) The multimodal ferroptosis nanoinducer was administered to tumor-bearing mice via tail vein injection for in vivo anti-colorectal cancer and drug safety evaluation.

[0059] Preferably, in step (A), the amount of the multimodal ferroptosis nanoinducer added to the culture system of colorectal cancer cells is 0.03%-10% of the total culture system liquid, which is 1:(50-200), for example, it can be 0.03%, 0.06%, 0.12%, 0.25%, 0.5%, 1%, 5%, 10%, etc.

[0060] Preferably, in step (A), the cell culture temperature is 25° C., and the cell culture time is 24 hours.

[0061] Preferably, in step (B), the dosage for the tumor-bearing mice is 100 μL.

[0062] Preferably, in step (B), the tumor-bearing mice are of balb / c breed and female gender, and the tumor-bearing modes are subcutaneous tumor-bearing and cecal in situ tumor-bearing.

[0063] In the present invention, the multimodal ferroptosis nanoinducer has achieved excellent anti-tumor effects in the treatment of colorectal cancer, and enhances the death of colorectal cancer cells by promoting cancer cell ferroptosis in a multimodal manner.

[0064] The technical solution of the present invention is further described below with reference to the accompanying drawings and through specific implementations. It should be understood by those skilled in the art that the specific implementations are only to help understand the present invention and should not be regarded as specific limitations of the present invention.

[0065] The sources of the components in the following examples are as follows: SN38 (purity 98%, Sigma), SAS (purity 98%, Sigma), ferrocene dicarboxylic acid (purity 98%, Sigma), bis(2-hydroxyethyl) disulfide, DSPE-PEG 2k (purity 98%, Sigma), THF (analytical grade, Sigma).

[0066] Example 1

[0067] This embodiment provides a multi-mode ferroptosis nano-inducing agent (FSS), and the multi-mode ferroptosis nano-inducing agent (FSS) is prepared by the following preparation method:

[0068] (1) Weigh 5 mg of Fc-ss-SN38 and pour it into a 2 mL plastic centrifuge tube, add 1 ml of tetrahydrofuran, and shake for 5 min to promote sample dissolution. If there is any undissolved part, ultrasonicate for 3 min to completely dissolve it to avoid the presence of insoluble matter, and prepare a 5 mg / ml mother solution; weigh 5 mg of Fc-ss-SAS and pour it into a 2 mL plastic centrifuge tube, add 1 ml of tetrahydrofuran, and shake for 5 min to promote sample dissolution. If there is any undissolved part, ultrasonicate for 3 min to completely dissolve it to avoid the presence of insoluble matter, and prepare a 5 mg / ml mother solution; weigh 1 mg of DSPE-PEG 2k Pour into a 2 mL plastic centrifuge tube and add 1 mL of tetrahydrofuran. Shake for 5 minutes to promote sample dissolution. If there is any undissolved part, sonicate for 3 minutes to completely dissolve it to avoid the presence of insoluble matter, and prepare a 1 mg / mL stock solution.

[0069] (2) Take 80 μL Fc-ss-SN38 mother solution, 20 μL Fc-ss-SAS, and 100 μL DSPE-PEG 2k The mother solution was placed in a 1.5 mL plastic centrifuge tube and shaken for 3 min to mix the three solutions evenly; the mixed solution was slowly dripped into pure water and stirred at room temperature overnight to obtain the multi-modal ferroptosis nanoinducer.

[0070] in, Figure 1 The TEM image of FSS provided in Example 1 is Figure 1 It can be seen that the multimodal ferroptosis nanoinducers are spherical particles with uniform particle size.

[0071] Application Example 1

[0072] We performed MTT assay to investigate the cytotoxicity of FSS to CT26 cells. Figure 2 ). The results showed that FSS exhibited superior cytotoxicity. In addition, Figure 3 Annexin V-FITC / PI double staining and subsequent flow cytometry analysis showed that the apoptosis induction rate of the FSS-treated group was 40%, indicating that FSS could significantly enhance tumor cell death. Then, in order to observe the ability of FSS to inhibit the proliferation of CT26 cells, a cell scratch assay was performed. Figure 4 As shown, the cell migration rate of the FSS-treated group at 24h and 48h was lower than that of the control group, indicating that FSS exhibited significant anti-tumor cell proliferation ability. The above results showed that FSS had significant effects of inducing apoptosis and inhibiting cancer cell proliferation, indicating that FSS has superior anti-tumor potential in vitro.

[0073] Based on the significant anti-tumor effect of FSS in vitro, the ferroptosis-related molecular mechanism of FSS-induced cell death in CT26 cells was further explored. The exploration projects mainly included intracellular oxidative stress markers MDA ( Figure 5 )、Fe(II)( Figure 6 ), ferrous ions ( Figure 7 ) and GSH( Figure 8 ) content. The MDA content in the FSS-treated group was 16 times that in the control group; the Fe(II) and total iron content in the FSS-treated group were higher than those in the control group, proving that FSS significantly caused iron overload in CT26 cells; the cysteine ​​and GSH content in the FSS-treated group were lower than those in the control group. These results indicate that FSS can cascade reduce the production of GSH.

[0074] Application Example 2

[0075] To verify the antitumor effect of FSS in the subcutaneous CT26 tumor model, FSS was injected intravenously via the tail vein, and the changes in tumor volume were monitored. Fig. 9 As shown, the tumor volume in the FSS-treated group increased the least, indicating that the use of FSS had a significant inhibitory effect on tumor growth. After the treatment was completed, the mice were humanely killed and the tumors were removed for observation and measurement. Compared with the control group (1493.12 mg), the average tumor weight in the FSS-treated group (496 mg) was the smallest, and the use of FSS once again showed an excellent in vivo antitumor effect. In order to observe the internal conditions of the tumor more microscopically, sections were prepared from the tumor tissue, as shown in Figure 1. Fig.10 and Fig.11 As shown in the figure, the results of Ki67 and TUNEL showed that the FSS-treated group had the least Ki-67 positive cells, while the TUNEL positive cells were more than the other groups. Semi-quantitative results showed that the Ki67 positive cells in the FSS-treated group were about one-third of the PBS-treated control group, while the TUNEL positive cells in the FSS-treated group were 3 times higher than those in the PBS-treated control group. The above results indicate that FSS significantly triggers necrosis and apoptosis and exerts the most effective inhibitory effect, indicating its powerful anti-tumor properties.

[0076] Based on the ability of FSS to trigger ferroptosis in monolayers of CT26 cells, the biological mechanisms of ferroptosis were further investigated in animal models by evaluating specific markers in subcutaneous CT26 tumor-bearing mice. Fig.12 As shown in the figure, the fluorescence signal of GPX4 in the FSS-treated group was weaker than that in the control group, indicating that the FSS-treated group had the most severe reduction in the ability to clear lipid peroxides in cells compared with the control group. In addition, compared with the control group, the fluorescence signal of Nrf2 in FSS was the weakest, further indicating that FSS caused the downregulation of Nrf2 in vivo ( Fig.13 These results suggest that FSS inhibits tumor growth through robust ferroptosis in tumors, indicating that FSS promotes tumor cell death and achieves antitumor effects through a multimodal cascade of ferroptosis in a subcutaneous CT26 tumor-bearing mouse model.

[0077] Application Example 3

[0078] In order to more objectively simulate the entire process of tumor occurrence, development and invasion in vivo, an orthotopic mouse colon cancer tumor model was constructed to more objectively evaluate the anti-tumor effect of FSS.

[0079] like Fig.14 As shown in the figure, after the treatment was completed, the mice were humanely killed and the tumors were removed for observation and measurement. Compared with the control group (1621.17 mg), the average tumor weight of the FSS-treated group (435 mg) was the smallest, and the use of FSS once again showed an excellent in vivo anti-tumor effect. Fig.15 and Fig.16 As shown in Figure 2, the results of Ki67 and TUNEL showed that the FSS-treated group had fewer Ki-67-positive cells, while more TUNEL-positive cells than the control group. Fig.17 As shown in the figure, the fluorescence signal of GPX4 in the tumor of the FSS-treated group was weaker than that of the control group, revealing that the lipid peroxide clearance ability of the cells in the FSS-treated group was most seriously decreased compared with the control group. Secondly, compared with the control group, the fluorescence signal of Nrf2 in FSS was weak, further indicating that FSS caused Nrf2 downregulation in the orthotopic CT26 tumor-bearing mouse model ( Fig.18 ).

[0080] The above results further illustrate the objective fact that FSS exerts its powerful anti-tumor effect through the cascade amplification of ferroptosis effects in the actual process of tumor growth, development and invasion in orthotopic models.

[0081] The applicant declares that the present invention illustrates the multi-mode ferroptosis nano-inducer and its preparation method and application through the above-mentioned embodiments, but the present invention is not limited to the above-mentioned embodiments, that is, it does not mean that the present invention must rely on the above-mentioned embodiments to be implemented. Those skilled in the art should understand that any improvement of the present invention, the equivalent replacement of the raw materials of the product of the present invention, the addition of auxiliary components, the selection of specific methods, etc., all fall within the protection scope and disclosure scope of the present invention.

Claims

1. Ferrocene-based drug dimer nanotherapeutics, It is characterized in that The ferrocene-based drug dimer nanotherapeutic agent is formed by self-assembly of Fc-ss-SN38 and Fc-ss-SAS to form nanoparticles, and by introducing DSPE-PEG 2k Prepared; The Fc-ss-SN38 and Fc-ss-SAS are obtained by chemically coupling SN38 or SAS with ferrocene dicarboxylic acid via bis(2-hydroxyethyl) disulfide, and the structural formula is as follows:

2. The method for preparing the ferrocene-based drug dimer nanotherapeutic agent according to claim 1, It is characterized in that The preparation method comprises the following steps: (1) Dissolve Fc-ss-SN38 and Fc-ss-SAS in tetrahydrofuran to obtain two prodrug solutions; 2k Dissolve in tetrahydrofuran to obtain DSPE-PEG 2k Solution; (2) The prodrug solution obtained in step (1) and DSPE-PEG 2k The solutions were mixed, slowly dripped into pure water, and stirred at room temperature overnight to obtain the multi-modal ferroptosis nanoinducer.

3. The preparation method according to claim 2, It is characterized in that In step (1), the concentration of the prodrug solution is 1-5 mg / mL; the DSPE-PEG 2k The concentration of the solution is 1-5 mg / mL.

4. The preparation method according to claim 3, It is characterized in that In step (1), the concentration of the prodrug solution is 5 mg / mL; the DSPE-PEG 2k The concentration of the solution was 5 mg / mL.

5. The preparation method according to claim 4, It is characterized in that In step (2), the volume ratio of the Fc-ss-SN38 prodrug solution to the Fc-ss-SAS prodrug solution is 1:9, 1:4, 1:1, 4:1 or 9:

1.

6. The preparation method according to claim 5, It is characterized in that The volume ratio of the Fc-ss-SN38 prodrug solution to the Fc-ss-SAS prodrug solution is 4:

1.

7. The preparation method according to claim 2, It is characterized in that In step (2), the reaction temperature is 4-60°C, and the reaction time is 12-48h.

8. The preparation method according to claim 7, It is characterized in that In step (2), the reaction temperature is 25° C. and the reaction time is 24 h.

9. The preparation method according to claim 2, Features: The Fc-ss-SN38 or Fc-ss-SAS is replaced with Fc-ss-AA, Fc-ART, Fc-ss-PTX, Fc-ss-IMI, Fc-ss-R848, Fc-ss-TRA, Fc-ss-CEL or Fc-ss-ATRA.

10. Use of the ferrocene-based drug dimer nanotherapeutic agent according to claim 1 or the ferrocene-based drug dimer nanotherapeutic agent prepared by the preparation method according to any one of claims 2 to 9 in any of the following: (1) Multimodal induction of ferroptosis in colorectal cancer cells; (2) Preparation of drugs for the treatment of colorectal cancer.

Citation Information

Patent Citations

  • Bioactive matter conjugate as well as preparation method and application thereof

    CN113603703A

  • Disulfide bond bridged SN38 dimer prodrug as well as self-assembled nanoparticles, preparation method and application of disulfide bond bridged SN38 dimer prodrug

    CN115844891A

  • Preparation and application of micromolecular self-assembled nano prodrug combined with chemotherapy and ferroptosis treatment

    CN116327774A

  • Bioactive conjugate, preparation method therefor and use thereof

    WO2019114666A1